Slide 1: Welcome to the 2Q26 webinar
Welcome to the 2Q26 webinar 21st August 2026
Slide 2: Today's agenda
Today’s agenda ▪ This is Modulight ▪ Q2 and H1 in nutshell ▪ Financial highlights ▪ R&D pipeline progress ▪ Outlook ▪ Summary ▪ Q&A
Slide 3: We fight cancer with science and technology
We fight cancer with science and technology ▪ We are a life science company that designs and manufactures laser devices for the treatment of cancer and eye diseases ▪ We also manufacture products for other high- value applications such as flow cytometry, microscopy, semiconductor, quantum, and defen
Slide 4: modulight
modulight
Slide 5: Q2 in brief
Q2 in brief ▪ Pipeline is progressing (36 projects) and customer base & product mix continues to diversify ▪ Phase 3 project patient recruitment completed earlier than expected Significant customer ▪ Approved as supplier to one of the project progresses toward world’s largest semiconductor company c
Slide 6: Financial highlights Apr-Jun 2026
Financial highlights Apr-Jun 2026 ▪ PPT business continues good progress; revised pricing structure & introduced better long-term predictability ▪ Revenue 18% lower than in the Revenue EBITDA EBIT corresponding period of 2025, influenced also by early-stage prototype deliveries to large customers ▪
Slide 7: Financial highlights Jan-Jun 2026
Financial highlights Jan-Jun 2026 ▪ PPT business continued good progressing in terms of number of indications and sites, 137% increase in 1H26 vs 2025 ▪ Revenue 13% lower than in the Revenue EBITDA EBIT corresponding period of 2025 ▪ EBITDA 12% which is an improvement of 29% due to continuous focus
Slide 8: Key figures
Key figures Group EUR 1,000 unless otherwise noted 4–6/2026 4-6/2025 1–6/2026 1-6/2025 1–12/2025 1) Revenue 1,604 1,962 3,099 3,568 7,069 EBITDA 37 -43 367 -625 -168 EBITDA - % 2,3% -2.2% 11.8% -17.5 % -2.4 % Operating result (EBIT) -1,346 -1,055 -2,410 -2,640 -4,648 Operating result (EBIT) - % -83.
Slide 9: Growth in the R&D pipeline – phase 3 project completed patient recruitment faster than expected
Growth in the R&D pipeline – phase 3 project completed patient recruitment faster than expected ▪ R&D pipeline grew to 36 (32) projects and growth coming from very large Number of projects with commercialization potential companies – aim in all projects is to commercialize our own products 40 ▪ PPT
Slide 10: Modulight's customer base
Modulight’s customer base Customer ownership Very large companies share 40 in customer portfolio 35 increases 30 ▪ 44% have over 1bn revenue 25 ▪ 64% of customers are listed companies 20 ▪ 60% are established 15 companies ▪ 31% are privately owned 10 ▪ 6% are research companies 5 0 2Q23 3Q23 4Q23 1Q
Slide 11: Outlook
Outlook The company expects to grow its revenues and EBITDA in the financial year 2026. The purpose of introducing guidance is to increase transparency and improve the predictability of the company’s financial development for investors and other stakeholders. The guidance reflects management’s curre
Slide 12: Summary
Summary ▪ Pipeline is increasing and share of large customers is now 44% (35%) ▪ Phase 3 project patient recruitment completed earlier than expected ▪ Approved supplier to one of the world’s largest semiconductor companies ▪ EBITDA improved 185% from 2Q25, remaining positive and reaching 2% Q2 & Sal
Slide 13: Thank you!
Thank you! Questions?